In Brief This Week: Quest Diagnostics; Thermo Fisher; DiagnoCure; TGen; Med BioGene | GenomeWeb

NEW YORK (GenomeWeb News) – Quest Diagnostics has entered into an accelerated share repurchase deal with Morgan Stanley to buyback about $350 million of Quest's common stock as part of its share repurchase program. The deal is expected to complete in the fourth quarter. The company last month announced the board approved an increase to its share repurchase authorization of $1.0 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.